Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
Date:11/29/2007

WILMINGTON, Del., Nov. 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX(R) (anastrozole) for its licensed breast cancer indications until June 2010. Prior to pediatric exclusivity being granted by the FDA, the patent was due to expire in December 2009.

ARIMIDEX is currently approved in the US for the for the following indications:

-- The adjuvant treatment (treatment following surgery with or without

radiation) of postmenopausal women with hormone receptor positive early

breast cancer (Sub Part H approval granted in 2002, final approval in

2005).

-- The first-line treatment of postmenopausal women with hormone receptor

positive or hormone receptor unknown locally advanced or metastatic

breast cancer (granted in 2000).

-- The treatment of advanced breast cancer in postmenopausal women with

disease progression following tamoxifen therapy. Patients with hormone

receptor-negative disease and patients who did not previously respond

to tamoxifen therapy rarely responded to ARIMIDEX (granted in 1995).

Dr. John Patterson, Executive Director of Development at AstraZeneca said "Pre-clinical and clinical data supported the investigation of the therapeutic potential of ARIMIDEX in pediatric conditions that manifest symptoms resulting from increased estrogen production, for example: gynecomastia in pubertal boys and precocious puberty in girls with McCune-Albright Syndrome (MAS). While pleased to have been able to work with the FDA in investigating the potential benefits of ARIMIDEX in these settings, AstraZeneca will not be seeking an indication in either of these pediatric conditions based on trial results."

In the US, ARIMIDEX sales reached $507 million for the nine months of 2007. ARIMIDEX has a
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... , ... METTLER TOLEDO has announced an upcoming online symposium ... Pfizer, and Merck. This free online seminar will be held on September ... informed decisions with limited process understanding. Established methods have been developed to ...
(Date:8/4/2015)... ... 04, 2015 , ... Half of consumers are considering a ... increasingly influential in their choice of practitioner, according to new survey data from ... Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments and ratings ...
(Date:8/4/2015)... ... ... The results of a three year clinical trial for the Argus II, a ... blindness, were published on June 23, 2015 in Ophthalmology , the journal of ... more commonly known as the “bionic eye,” is safe and effective for long-term treatment ...
(Date:8/4/2015)... ... August 04, 2015 , ... Rock Your Hair, http://www.rockyourhair.com ... Bash Tour. In addition, they have signed Lexi Noel, dubbed the Teen Beauty Queen ... print and overall branding opportunities for the company. , The Pop & Rock ...
(Date:8/4/2015)... , ... August 04, 2015 , ... More than 700 ... renewed their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard ... each other. Following the ceremony was a reception, with music by the Moonlight ...
Breaking Medicine News(10 mins):Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Rock Your Hair Signs On As Title Sponsor For The HYPE! Projects Pop & Rock Beauty Bash Tour 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2
... one-fifth of primary care physicians in the US follow ... tests they recommend, according to Dr. Robin Yabroff from ... percent followed guidelines for some of the tests they ... guidelines for any of the screening tests they recommended. ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, Oct. 13 ... in poor countries could help HIV-infected mothers and their infants ... Currently, doctors lower the risk of transmission of mother-to-baby HIV ... and to babies right after. About half of the babies ...
... Ore According to new research conducted at Oregon ... power to combat fibromyalgia a medical disorder characterized ... in the November 10 online edition of the journal ... "Previous research suggests that the most successful treatment ...
... both medical progress and unmet needs in the ... Philadelphia will house the Network Coordinating Center for ... Research Network. Launched this year with ... federal government,s Maternal Child Health Bureau, the Network ...
... HealthDay Reporter , WEDNESDAY, Oct. 13 (HealthDay News) -- ... brain shrinkage in old age, which in turn helps stem ... reveals. "We have always been in search of the ... noted Kirk I. Erickson, an assistant professor of psychology at ...
... Gordon HealthDay Reporter , WEDNESDAY, Oct. 13 (HealthDay ... Virginia may have elevated blood pressure, according to new research ... "The real thrust of this research is trying to ... screen for hypertension [high blood pressure] in children. And, while ...
Cached Medicine News:Health News:Not all doctors follow cancer screening guidelines 2Health News:Studies Tout Alternative HIV Regimens for Women, Babies 2Health News:Studies Tout Alternative HIV Regimens for Women, Babies 3Health News:OHSU research suggests yoga can counteract fibromyalgia 2Health News:Children's Hospital coordinates new network for developmental disabilities 2Health News:Walking 6 to 9 Miles a Week May Help Save Memory 2Health News:Walking 6 to 9 Miles a Week May Help Save Memory 3Health News:Nearly 1 in 5 W.Va. 5th Graders May Have High Blood Pressure 2Health News:Nearly 1 in 5 W.Va. 5th Graders May Have High Blood Pressure 3
(Date:8/4/2015)... Aug. 4, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... epigenetic drivers of cancer, will be presenting at the 2015 ... 1:55 p.m. ET (10:55 a.m. PT) in New ... president and CEO of Mirati, will provide a corporate overview. ... be accessible on the "Investors" page of Mirati,s corporate website ...
(Date:8/4/2015)... MADISON, Wis. , Aug. 4, 2015 /PRNewswire/ ... an agreement with Restore Health, a company specializing ... of a double-blind clinical trial, designed to evaluate ... drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). ... Ironshore. Restore Health originally partnered with ...
(Date:8/3/2015)...  Luminex Corporation (NASDAQ: LMNX ) today announced ... 2015.  Financial and operating highlights for the quarter include ... revenue by 6 percent to $58.9 million, over the ... 2015 assay revenue by 22 percent to $24.2 million ... , Increased Q2 2015 royalty revenue by 17 percent ...
Breaking Medicine Technology:Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16
... Vitoss engineered to ... porosity and structure. -TCP ... well in spinal arthrodesis ... defects due to trauma ...
... is a synthetic porous ceramic graft material composed ... mineral phase that comprises 70% of human bone. ... scaffold that allows the attachment of bone forming ... networks within granules as well as between each ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Baby Weitlaner retractor, blunt, 4"....
Medicine Products: